SCHEMBL5706358

SCHEMBL5706358

CN(c1cccc(C#C[SiH](C)C)c1)C1CC1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 1/20 0.34
GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4508228 0.79 JAK1 (0.36) JAK1GRM5
SCHEMBL4518143 0.78 JAK1 (0.36) JAK1
SCHEMBL5706343 0.75 DPP4 (0.46)
SCHEMBL24054526 0.70 ACHE (0.42)
SCHEMBL4513979 0.69 FFAR1 (0.57)
SCHEMBL4513984 0.69 FFAR1 (0.57)
SCHEMBL28783783 0.68 HTR3E (0.47)
SCHEMBL4365727 0.68 HTR2A (0.40)
SCHEMBL24054689 0.68 CYP3A4 (0.41)
SCHEMBL1419786 0.68 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696899-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2006-09-06 EP disclosed
WO-2005058301-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2005-06-30 WO disclosed